Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.
- Annual Screening with Chest X-Ray Does Not Reduce Lung Cancer Deaths
(Posted: 12/02/2011) - Annual screening for lung cancer using a standard chest x-ray does not reduce the risk of dying from lung cancer when compared with no annual screening, according to findings from the NCI-led Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial.
- Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients
(Posted: 12/02/2011) - A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin in terms of overall survival, according to a report published online October 21 in The Lancet.
- Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
(Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.
- Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit
(Posted: 11/23/2011) - In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.